WideCells Group


Attendance at Brazilian Obstetrics and Gynaecology Conference

News Release | PressRoom

WideCells Group (‘WideCells’ or ‘the Company’)

Attendance at Brazilian Obstetrics and Gynaecology Conference

 

WideCells Group PLC ('WideCells' or the 'Company'), the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to announce its attendance at the Obstetrics and Gynaecology Conference inSão Paulo, Brazil, 25-26 May 2017.  At the conference, Dr Niranjan Bhattacharya, a preeminent figure in the stem cell industry and founding member of CellPlan’s Stem Cell Panel, will be making a presentation on stem cell technology and the developments both he and WideCells are driving within the industry. 

Dr Bhattacharya’s expansive career in medical research focuses on cell and tissue therapy in degenerative disease and placental umbilical cord blood.  He is currently the Head of the Depatment and Chair Professor of the Department of Regenerative Medicine and Translational Science, and is Director General of the Public Cord Blood Bank and Calcutta School of Tropical Medicine in Kolkata, India.  Alongside this, he is a senior consultant in Obstetrics and Gynaecology and General Surgery in a number of premier private hospitals in Kolkata, India. Furthermore, as a founding member of the Stem Cell Panel, he is responsible for reviewing patient cases for CellPlan, the Company’s innovative stem cell insurance product, providing and managing a panel of expert doctors who provide secondary medical opinion to WideCells/CellPlan patients, and ultimately helping to ensure that the Company’s competitive service offering and insurance policy remains fully reflective of industry developments.

For further information on the conference please visit http://www.sogesp.com.br/eventos/xi-jornada-de-obstetricia-e-ginecologia-de-campinas-e-regiao-e-xi-encontro-dos-ex-residentes

 

**ENDS**

 

For further information, please visit the Company’s website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

WideCells Group

CEO – João Andrade

Tel:  +351 919 033 171

Smaller Company Capital Ltd

Broker – Jeremy Woodgate & Rupert Williams

Tel: +44 (0) 20 3651 2912

Shard Capital Partners LLP

Broker – Damon Heath & Erik Woolgar

Tel: +44 (0) 207 186 9950

St Brides Partners Ltd

PR – Elisabeth Cowell & Charlotte Page

Tel: +44 (0) 20 7236 1177

 

Notes to Editors

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. The Directors believe that the use of cord blood stem cells for transplant will drive one of the next important phases in medicine and is therefore developing market leading products in complementary, strategic areas which are designed to take advantage of substantial market opportunities in one of the fastest growing segments in the healthcare industry.  With this in mind, it has created three divisions:

  • CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.
  • WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising on stem cell storage.
  • WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

 

Stem Cell Fast Facts:

  • Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow – WideCells will focus on promoting the collection and storage of this.
  • Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.
  • 82 illnesses can currently be treated using stem cell procedures.
  • Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands.

 

This announcement contains inside information for the purposes of Article 7 of MAR.

 

 

 

 

 

Sources

WideCells Group PlC